2Seta T,Noguchi Y,Shimada T,et al.Treatment of acute pancreatitis with protease inhibitors:a meta-analysis.Eur J Gastroenterol Hepatol,2004,16:1287-1293.
3Di Francesco V,Mariani A,Angelini G,et al.Effects of gabexate mesilate,a protease inhibitor,on human sphincter of Oddi motility.Dig Dis Sci,2002,47:741-745.
5Mayumi T,Ura H,Arata S,et al.Evidence-based clinical practice guidelines for acute pancreatitis:proposals.J Hepatobiliary Pancreat Surg,2002,9:413-422.
6Freeman ML.Prevention of post-ERCP pancreatitis:pharmacologic solution or patient selection and pancreatic stents? Gastroenterology,2003,124:1977-1980.
7Andriulli A,Solmi L,Loperfido S,et al.Prophylaxis of ERCP-related pancreatitis:a randomized,controlled trial of somatostatin and gabexate mesylate.Clin Gastroenterol Hepatol,2004,2:713-718.
二级参考文献5
1Aliperti G. Complications related to diagnostic and therapeutic endoscopic retrograde cholangiopancreatography. Gastrointest Endosc Clin North Am, 1996,6: 379-407.
2Chen YK, Foliente RL, Santoro MJ, et al. Endoscopic sphincterotomy-induced pancreatitis: Increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol ,1994,89: 327-333.
3Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med, 1996, 335:919-923.
4Matsumura T, Yada S, Miyoshi Y, et al. Effect of synthetic protease inhibitor on the sphincter of Oddi function in dogs. Nippon Shokakibyo Gakkai Zasshi, 1991, 88:2663-2670.
5Di Francesco V, Marriani A, Angelini G , et al. Effects of gabexate mesilate,a protease inhibitor, on human sphincter of Oddi motility.Dig Dis Sci, 2002, 47:741-745.
